A new in-plate, zero-disruption design enables reproducible organoid culture, downstream processing, and high-resolution imaging in a single 3D cell culture plateA new in-plate, zero-disruption design enables reproducible organoid culture, downstream processing, and high-resolution imaging in a single 3D cell culture plate

TheWell Bioscience Launches VitroPrime™ 3D Culture and Imaging Plate for Organoid and 3D Cell Culture Workflows

2026/02/09 22:02
3 min read

A new in-plate, zero-disruption design enables reproducible organoid culture, downstream processing, and high-resolution imaging in a single 3D cell culture plate

MONMOUTH JUNCTION, N.J., Feb. 9, 2026 /PRNewswire/ — TheWell Bioscience today announced the launch of the VitroPrime™ 3D Culture and Imaging Plate, a next-generation 3D cell culture plate engineered to support organoid and advanced 3D cell culture workflows with minimal physical disturbance. The VitroPrime™ 3D Culture and Imaging Plate enables long-term culture, fixation, immunofluorescence staining, and high-resolution imaging to be performed entirely in-plate—eliminating sample transfer while preserving fragile hydrogel-based 3D structures.

Through a unique combination of sample-locking architecture, passive media exchange, and imaging-grade optics, the VitroPrime™ 3D Culture and Imaging Plate addresses persistent challenges in 3D cell culture, including hydrogel floating, sample rotation, and sample loss during routine handling. By minimizing manual manipulation and vessel-to-vessel transfers, the plate improves reproducibility, supports longitudinal studies, and enables consistent data generation across experiments.

Most current 3D cell culture systems, including organoid models, rely on culture vessels originally designed for 2D monolayer cultures rather than delicate, hydrogel-based 3D constructs. As a result, routine media exchange and downstream processing frequently disrupt 3D architecture and spatial organization. In addition, fixation, staining, and imaging often require transferring samples between vessels, increasing the risk of structural damage, sample loss, and experimental variability—an especially costly challenge for organoid workflows, where samples are often rare, time-intensive to generate, and difficult to replace. These limitations make reliable long-term culture, high-resolution imaging, and laboratory automation difficult to achieve within a single 3D cell culture plate.

The VitroPrime™ 3D Culture and Imaging Plate was engineered to overcome these challenges by enabling a true end-to-end 3D workflow—from sample seeding and long-term culture to downstream processing and imaging—within a single vessel, with zero sample transfer and minimal physical disturbance.

“For years, we’ve spoken with researchers around the world who struggle to find the right culture vessel for 3D organoid workflows—one that can prevent hydrogel floating, allow live-cell tracking, enable easy media exchange and sample fixation without sample loss, and support high-resolution imaging,” said John Huang, CEO of TheWell Bioscience. “It took several years of rational design and iterative development to translate these unmet needs into a practical, scalable solution.”

At the core of the VitroPrime™ plate is a dedicated lateral media-exchange channel that enables passive, disturbance-free diffusion of nutrients, stains, and fixatives while preserving the integrity of delicate 3D constructs. An integrated anti-floating and anti-rotation design ensures stable positioning during longitudinal monitoring, organoid development studies, live-cell imaging, and high-content analysis. The plate also features an ultra-clear, premium cover-glass bottom optimized for high-resolution and confocal imaging.

The VitroPrime™ 3D Culture and Imaging Plate integrates seamlessly with TheWell Bioscience’s end-to-end, xeno-free 3D cell culture platform, including VitroGel® hydrogels, RocketCell™ media, CytoGrow™ growth factors, and Cyto3D® downstream analysis reagents. Together, the platform delivers a defined, scalable, and automation-ready workflow for more relevant and reproducible advanced 3D cell culture models.

VitroPrime™ 3D Culture and Imaging Plate is currently available in 6-, 12- and 96-well formats. For more information, please visit www.thewellbio.com

About TheWell Bioscience Inc.
TheWell Bioscience delivers a comprehensive, end-to-end, xeno-free platform for robust and reproducible 3D cell models. Its integrated ecosystem of xeno-free hydrogels, media, cultureware, and downstream reagents eliminate animal-derived variability, support scalable applications in precision medicine, cell therapy, and biomanufacturing, and advances New Approach Methodologies (NAMs) through more human-relevant in vitro models.

Contact:
Kyra Baricaua
9738554955
408834@email4pr.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/thewell-bioscience-launches-vitroprime-3d-culture-and-imaging-plate-for-organoid-and-3d-cell-culture-workflows-302681692.html

SOURCE TheWell Bioscience Inc.

Market Opportunity
Cellframe Logo
Cellframe Price(CELL)
$0.0682
$0.0682$0.0682
+2.55%
USD
Cellframe (CELL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Hadron Labs Launches Bitcoin Summer on Neutron, Offering 5–10% BTC Yield

Hadron Labs Launches Bitcoin Summer on Neutron, Offering 5–10% BTC Yield

Hadron Labs launches 'Bitcoin Summer' on Neutron, BTC vaults for WBTC, eBTC, solvBTC, uniBTC and USDC. Earn 5–10% BTC via maxBTC, with up to 10x looping.
Share
Blockchainreporter2025/09/18 02:00
South Korea Launches First Won-Backed Stablecoin KRW1 on Avalanche

South Korea Launches First Won-Backed Stablecoin KRW1 on Avalanche

South Korea made history this week by launching its first Korean won-backed stablecoin.
Share
Brave Newcoin2025/09/19 03:15
Curve Finance votes on revenue-sharing model for CRV holders

Curve Finance votes on revenue-sharing model for CRV holders

The post Curve Finance votes on revenue-sharing model for CRV holders appeared on BitcoinEthereumNews.com. Curve Finance has proposed a new protocol called Yield Basis that would share revenue directly with CRV holders, marking a shift from one-off incentives to sustainable income. Summary Curve Finance has put forward a revenue-sharing protocol to give CRV holders sustainable income beyond emissions and fees. The plan would mint $60M in crvUSD to seed three Bitcoin liquidity pools (WBTC, cbBTC, tBTC), with 35–65% of revenue distributed to veCRV stakers. The DAO vote runs from up to Sept. 24, with the proposal seen as a major step to strengthen CRV tokenomics after past liquidity and governance challenges. Curve Finance founder Michael Egorov has introduced a proposal to give CRV token holders a more direct way to earn income, launching a system called Yield Basis that aims to turn the governance token into a sustainable, yield-bearing asset.  The proposal has been published on the Curve DAO (CRV) governance forum, with voting open until Sept. 24. A new model for CRV rewards Yield Basis is designed to distribute transparent and consistent returns to CRV holders who lock their tokens for veCRV governance rights. Unlike past incentive programs, which relied heavily on airdrops and emissions, the protocol channels income from Bitcoin-focused liquidity pools directly back to token holders. To start, Curve would mint $60 million worth of crvUSD, its over-collateralized stablecoin, with proceeds allocated across three pools — WBTC, cbBTC, and tBTC — each capped at $10 million. 25% of Yield Basis tokens would be reserved for the Curve ecosystem, and between 35% and 65% of Yield Basis’s revenue would be given to veCRV holders. By emphasizing Bitcoin (BTC) liquidity and offering yields without the short-term loss risks associated with automated market makers, the protocol hopes to draw in professional traders and institutions. Context and potential impact on Curve Finance The proposal comes as Curve continues to modify…
Share
BitcoinEthereumNews2025/09/18 14:37